Skip to main content
Javier Martínez-Picado

Javier Martínez-Picado

Institut de Recerca de la Sida - IrsiCaixa

Life & Medical Sciences

Javier Martínez-Picado is ICREA Research Professor at the irsiCaixa AIDS Research Institute in Barcelona, an institution that works to advance clinical research and translate results into patients care. He is also associate professor at the Univ of Vic. He received his PhD from the Univ of Barcelona where he subsequently became associate professor lecturing on different microbiology-related subjects. In 1996, he joined the Massachusetts General Hospital as postdoctoral fellow of the Harvard Medical School, where he engaged in AIDS research. In 2000, he obtained a position as biomedical researcher of the Spanish Health Department appointed to the Hosp Germans Trias in Badalona. In 2006 he obtained his current ICREA position. Dr. Martínez-Picado serves on different government, academic and industry advisory boards and has published extensively on virology and immunology subjects, mainly related to HIV pathogenesis, in international journals.

Research interests

The research of our group focuses on characterizing the immune-virological mechanisms of viral pathogenesis in human diseases, including HIV-1, Ebola virus, Arenaviruses, and more recently SARS-CoV-2. Our program has a translational character with the goal of investigating potential new viral therapeutic strategies, especially in the HIV/AIDS field, through both basic and applied research. We closely collaborate with other research groups within irsiCaixa, as well as with national and international biomedical institutes. Our programme focuses on three priority areas in the HIV research: 1) HIV cure, 2) Viral pathogenesis mediated by dendritic cells, 3) Extreme HIV infection phenotypes. During 2020, an additional research line in SARS-CoV2 has been incorporated to the team.

Selected publications

– Lempp F et al 2021, ‘Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodiesNature 598:342-7

– Bastard P et al 2021, ‘Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsSci Immunol 6(62):eabl4340

– Benet S, et al 2021, ‘Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesiclesJ Extracell Vesicles 10:e12046

– Perez-Zsolt D et al 2021, ‘SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cellsCell Mol Immunol 18:2676–8

– Puertas MC et al 2021, ‘VIP-SPOT: an innovative assay to quantify the productive HIV-1 reservoir in the monitoring of cure strategies‘ mBio 12:e00560-21

– Galvez C et al 2021, ‘Atlas of the HIV-1 reservoir in peripheral CD4 T cells of individuals on successful antiretroviral therapymBio 12(6):e03078-21

– Imaz A et al, 2020. ‘Dynamics of the decay of HIV RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naïve HIV-1-infected adults treated with bictegravir/emtricitabine/tenofovir alafenamideClin Infect Dis 73(7):E1991-9

– Vigon L et al 2021, ‘Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapyBiochem Pharmacol 192:114666

– Vieira V et al 2021, ‘An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+T-cell-mediated immune control in adultsPLoS Pathog 17:e1010090

– Millar JR et al 2021, ‘Early initiation of antiretroviral therapy following in utero HIV infection is associated with low viral reservoirs but other factors determine subsequent plasma viral reboundJ Infect Dis, 224, 11, 1925 – 1934.

– Molto J et al 2021, ‘Pharmacokinetic/pharmacody-namic analysis of romidepsin used as an HIV latency reversing agent‘  J Antimicrob Chemother 76:1032–40

ICREA Memoir 2021